SATSUMA PHARMS
PharmaSATSUMA PHARMS is a pharmaceutical company focused on Neurology. Key products include ATZUMI.
SATSUMA PHARMS at a Glance
- Strong track record with 100% execution quality across 5 trials
- Fast trial execution (14 months median completion)
SATSUMA PHARMS's Key Drugs
SATSUMA PHARMS's core commercial portfolio centers on ATZUMI, spanning Neurology — its most strategically important drugs approved in the last 15 years.
SATSUMA PHARMS's Recent FDA Approvals
SATSUMA PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SATSUMA PHARMS's Therapeutic Areas
SATSUMA PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SATSUMA PHARMS's Top Competitors
SATSUMA PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SATSUMA PHARMS Pipeline Snapshot
Active clinical trials for SATSUMA PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ATZUMI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/3 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-04-30
- Latest
- 2025-04-30
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges